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Summary: Ambulatory blood pressure and heart rate 
monitoring were used for comparing the antihypertensive 
effect of a 1 -week treatment with enalapril and lisinopril 10 
mg once daily (double-blind crossover placebo-controlled 
d y ) .  Welve outpatients with mild to moderate hyper- 
tension were treated. Both drugs had a significant and 
identical hypotensive effect. Neither drug affected the diur- 
nal rhythm of blood pressure or heart rate. Therefore the 
two drugs are equipotent antihypertensive agents. Both 
drugs inhibited ACE activity to a highly significant extent, 
but in this regard lisinopril was more effective than en- 
alapril. However, lisinopril's greater ACE inhibition was 
not accompanied by a greater hypotensive effect. The clin- 
ical value of this difference is not yet established. 
Key words: ACE inhibitors, enalapril, lisinopril, 24-h 
ambulatory blood pressure monitoring 
Introduction 
Enalapril, the prodrug of the angiotensin-converting 
enzyme (ACE) inhibitor enalaprilat,' is used in the treat- 
ment of hypertension. Lisinopril is the lysine analog of 
enalaprilat* and is also an ACE inhibit~r.~ Unlike enalapril, 
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lisinopril is directly active? There is also evidence to sug- 
gest that lisinopril produces more prolonged inhibition of 
plasma ACE5 and has a longer-lasting antihypertensive 
effect than enalapril.6 The antihypertensive effect of single 
doses of enalapril and lisinopril is known,7 but it is con- 
ceivable that the response might be different after several 
days of active therapy. To our knowledge, direct compara- 
tive data from treatment more than one day were unavail- 
able. On the other hand, it was conceivable that, enalapril 
and lisinopril being long-acting ACE inhibitors, there 
could be a greater response as plasma and tissue concen- 
trations rise over time. Our study was planned to clarify 
this question. 
Material and Method 
Twelve outpatients (5 males and 7 females) aged be- 
tween 44 and 66 years were selected and treated. All had 
mild to moderate essential hypertension (duration 2 to 4 
years). Their antihypertensive therapy was stopped be- 
cause of insufficient effect or side effects: the patients were 
without treatment for 2 to 3 weeks. No other drugs were 
used and no contraindications to ACE inhibitors were pre- 
sent. The study was approved by the ethical committee and 
all patients gave informed consent. No patient was with- 
drawn before receiving the test medications because of 
normalization of blood pressure (BP). The test medications 
were placebo, enalapril, and lisinopril, 10 mg/day given as 
monotherapy once a day between 7:OO and 8:OO a.m. 
Treatment was given according to a randomized, double- 
blind, crossover design. Each test medication was given 
for a double-blind period of 7 days, followed by a single- 
blind placebo period of 4 days before the next crossover. 
Fixed dose regimens are necessary for research purposes; 
on the other hand, they are not likely to be adequate for 
the long-term treatment of hypertension: therefore, the 
duration of the treatment with the individual test medica- 
tions was limited to 7 days. Hypmtension was defined by 
a mean diastolic BP of between 95 and 115 mmHg, this 
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being the mean value of a 24-h ambulatory blood pressure 
monitoring (ABPM). Routine prestudy clinical laboratory 
tests were either normal or the abnormalities were clini- 
cally irrelevant. Blood samples and laboratory plus renin 
estimations were taken 24 h after the last dose of the 1- 
week treatment periods and 40 h before the ABPM. Base- 
line measurements of BP were obtained from the same ann 
throughout using simultaneously a mercury sphygmo- 
manometer and a Disetronic CH-Druck@ equipment.8 
Afterward, BP and heart rate (HR) were automatically 
measured with the CH-Druck equipment: two times per 
hour between 8:OO and 22:OO h (daily period) and once per 
hour between 22:OO and 8:OO h (night period). Again at the 
end of the ABPM, BF and HR were checked simultane- 
ously. The mean difference between manual and CH- 
Druck BP was less than 3 mmHg (range: -2 to +2 mmHg 
for systolic B P  0 + 3 mmHg for diastolic BP). ABPM was 
obtained 24 to 26 h after the last dose and during the last 
24-h period of the 1 -week treatment periods. Adverse 
events were recorded in response to the question: “Have 
you had any symptoms or problems since your last visit?’ 
All data were analyzed by means of a paired f-test and by 
calculation of the area under the curve (AUC) of the 
ABPM. Both methods gave identical statistical values. The 
presentation of the clinical data (figures) was better with 
the paired t-test analysis and therefore this method was 
used for presentation of the results. 
Results 
The portable automatic CH-Druck equipment was well 
accepted by the patients and functioned optimally. All 
patients ended the study with complete ABPM profiles. 
Systolic Blood Pressure 
Pretreatment values were similar: placebo 170.7f6.8; 
enalapril 176.5f9.5; lisinopril 176k7.9 mmHg (mean_+ 
SD). Placebo had no effect. As shown in Figure 1, both 
drugs reduced systolic BP 5.5 h postdosing (hollow area, 
~ 0 . 0 5 ) .  The hypotensive effect was slightly faster with 
enalapril (2.5 h: 165.859.3) than with lisioopril (5.0 h: 
165.1 f 14.1). Nonetheless the global hypotensive effect was 
similar for enalapril and lisinopril. The hypotensive effect 
was also similar at the 24th h (enalapril: 162.0f6.9, lisin- 
opril: 160. I k6.2). The diurnal rhythm was not changed. 
Diastolic Blood Pressure 
The pretreatment values were similar: placebo 102.3k 
3.2; enalapril 104.8f3.8; lisinopril 108.8k5.4 mmHg. 
Placebo had no effect. As shown in Figure 2, the hypoten- 
sive effect was similar for both drugs and was significant 
6 h postdosing: enalapril 99.1 k8.5, lisinopril 97.3f4.8 
mmHg (hollow area of Fig. 2, ~ ~ 0 . 0 5 % ) .  The circadian 
rhythm was not affected. 
Time of day 
FIG. 1 Systolic blood pressure mean of 12 patients. + SBP plac 
bo; -E- SBP lisinopril; +- SBP enalapril. Light-shaded area: I 
difference between treatment; dark-shaded area: No difference b 
tween lisinopd and placebo, but enalapril different from placebo I 
lisinopril; white area: no difference between treatments but both re 
imens differ from placebo. r-test (@%) at each time point. 
Heart Rate 
Neither placebo nor the test dwgs affected HR to ar 
significant extent (Fig. 3). 
Renin 
As shown in Figure 4, basal values were similar for i 
treatment periods: placebo 3.0f0.3; enalapril 2.9f0. 
lisinopril 2.8f0.2 ng/ml. Placebo had no effect. As ev 
dence for the ACE inhibition, serum renin levels increw 
significantly ( ~ 4 . 0 1 )  after both enalapril and lisinopn 
However, the effect of lisinopril was significantly great1 
than that of endapril: 4.7 10.3 after enalapril; 6.6f0.4 aft1 
lisinopril (pcO.01). 
Side Effects 
Few side effects were observed. One patient complaine 
of mild nausea at Day 2 with both drugs. Another patier 
complained of mild headache with enalapril on Day : 
Drug-related effects on the laboratory results were nc 
detectable. 
Discussion 
Oftice blood pressures have been the primary basis fc 
the physician’s decisions in the diagnosis and treatment c 
hypertension. In some patients, however, the office pre! 
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Time of day 
FK;. 2 Diastolic blood pressure mean of 12 patients. - DBP place- 
bo; + DBP lisinopril; *DBP enalapril. Shaded area: no differ- 
ence between treatments as well as no difference compared with 
placebo; white area: significant difference between placebo and both 
yeatments; no difference between lisinopril and enalapril. r-test 
(p<5%) at each time point. 
sures may be misleading. ABPM offers complementary 
relevance to the value of office blood pressures and may 
improve treatment9. lo by providing information about the 
risk of developing clinical complications of hypertension.” 
90 
85 k 
Time of day 
FIG. 3 Heart rate mean of 12 patients. - HR placebo; + HR 
lisinopril; * HR enalapril. No difference between treatments (t-test 
NS). 
4 I 
” Placebo Lisinopril Enalapril 
FIG. 4 Serum renin levels mean of 12 patients: lbefore  dose.; 0 2 4  
h after dose. Basal values: no difference; enalapril vs. baseline: 
pCo.01; lisinopril vs. baseline: p4.01; lisinopril vs. enalapril: pd.01. 
Our study confirms the optimal function of the CH-Druck 
equipment and ABPM was important in assessing the anti- 
hypertensive effects of the tested drugs. Our data confirm 
the results of the single dose study by Dews er ~ z f . : ~  while 
both drugs were equally effective and potent for the treat- 
ment of hypertension, the greater renin-inhibiting effect of 
lisinopril was not reflected by a greater antihypertensive 
effect. The antihypertensive effect of enalapril and lisino- 
pril was similar (duration and magnitude) and persisted for 
24 h. The diurnal profile of BP and HR were not affected 
by treatment. On the other hand, our data do not confirm 
the results of the single dose study by Millar er aL,6 where 
the antihypertensive effect of lisinopril was longer than 
that of enalapril. Obviously, the response of the drugs is 
different on repeated treatment. We used a fixed dose, and 
therefore our data are not sufficient for judging the effect 
of different doses. 
In spite of a similar antihypertensive effect, the renin in- 
hibiting effect of lisinopril was superior. Clearly, the phys- 
iologic effects of enalapril and lisinopril (and all known 
ACE inhibitors) are not clearly related to plasma renin 
alone. Indeed it has been known for some time that re- 
sponses of patients with hypertension to ACE inhibitors 
cannot be predicted by renin profiling alone.’)-l6 Brady- 
kinin, prostacyclin, and other humoral factors may play an 
important role in the pharmacologic effect of renin 
Renin inhibitors seem to be effective in pre- 
venting progression of ventricular dysfunction and may 
delay or prevent the appearance of heart failure:l7, I *  the 
full effect of these drugs, however, develops slowly and it 
may take more than 12 weeks to become maximal. Ob- 
viously our data from a 1-week treatment cannot be extrap- 
olated for the long-term treatment of patients with heart 
failure and, as Sir Arthur Conan Doyle said, “It is a capital 
mistake to theorize before one has data.” However, since 
the greater renin-inhibiting effect of lisinopril is not ac- 
companied by a greater antihypertensive effect, it would 
be interesting to compare their long-term effect in the mat- 
ment of heart failure. + 
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